nach oben

Cancer Causes & Control

Erschienen in:

10.05.2016 | Original Paper

Antidepressant use and circulating prolactin levels

verfasst von: Katherine W. Reeves, Olivia I. Okereke, Jing Qian, Shelley S. Tworoger, Megan S. Rice, Susan E. Hankinson

Erschienen in: Cancer Causes & Control | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine whether antidepressants (AD), specifically selective serotonin reuptake inhibitors (SSRIs), are linked to elevated prolactin levels among the general population.

Methods

Circulating prolactin levels were available for 4593 healthy participants in the Nurses’ Health Study (NHS) and NHS2, including 267 AD users. We fit generalized linear models to calculate and compare adjusted mean prolactin levels between AD users and non-users and further among SSRI users. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for “elevated” prolactin levels (>11 ng/mL) comparing AD users to non-users. We evaluated AD use and change in prolactin levels among 610 NHS participants with two measurements an average of 11 years apart.

Results

Adjusted geometric mean prolactin levels were similar among SSRI users (13.2 ng/mL, 95 % CI 12.2–14.4), users of other classes of ADs (12.7 ng/mL, 95 % CI 11.0–14.6), and non-users (13.1 ng/mL, 95 % CI 12.8–13.4). Neither AD use (OR 1.17, 95 % CI 0.89–1.53) nor SSRI use (OR 0.95, 95 % CI 0.66–1.38) was associated with elevated prolactin levels. Change in prolactin levels was similar across women who started, stopped, consistently used, or never used ADs.

Conclusions

This study does not support the hypothesis that AD use would influence breast cancer risk via altered prolactin levels. These results provide some evidence that use of ADs to treat depression or other conditions may not substantially increase prolactin levels in the majority of women.

Pratt LA, Brody DJ, Gu Q (2011) Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS Data Brief: 1–8

Olfson M, Marcus SC (2009) National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66:848–856CrossRefPubMed

Emiliano AB, Fudge JL (2004) From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29:833–846CrossRefPubMed

Balsa JA, Sanchez-Franco F, Pazos F, Lara JI, Lorenzo MJ, Maldonado G et al (1998) Direct action of serotonin on prolactin, growth hormone, corticotropin and luteinizing hormone release in cocultures of anterior and posterior pituitary lobes: autocrine and/or paracrine action of vasoactive intestinal peptide. Neuroendocrinology 68:326–333CrossRefPubMed

Madhusoodanan S, Parida S, Jimenez C (2010) Hyperprolactinemia associated with psychotropics—a review. Hum Psychopharmacol 25:281–297CrossRefPubMed

Tikk K, Sookthai D, Fortner RT, Johnson T, Rinaldi S, Romieu I et al (2015) Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case–control study. Breast Cancer Res 17:49CrossRefPubMedPubMedCentral

Tikk K, Sookthai D, Johnson T, Rinaldi S, Romieu I, Tjonneland A et al (2014) Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Ann Oncol 25:1422–1428CrossRefPubMed

Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA et al (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 73:4810–4819CrossRefPubMedPubMedCentral

Tworoger SS, Rice MS, Rosner BA, Feeney YB, Clevenger CV, Hankinson SE (2015) Bioactive prolactin levels and risk of breast cancer: a nested case–control study. Cancer Epidemiol Biomarkers Prev 24:73–80CrossRefPubMed

10.

Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814–6819CrossRefPubMed

11.

Tworoger SS, Eliassen AH, Sluss P, Hankinson SE (2007) A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25:1482–1488CrossRefPubMed

12.

Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66:2476–2482CrossRefPubMed

13.

Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL et al (2013) Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes Control 24:741–748CrossRefPubMedPubMedCentral

14.

Clevenger CV, Furth PA, Hankinson SE, Schuler LA (2003) The role of prolactin in mammary carcinoma. Endocr Rev 24:1–27CrossRefPubMedPubMedCentral

15.

Tworoger SS, Hankinson SE (2008) Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 13:41–53CrossRefPubMed

16.

Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ et al (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87:1297–1302CrossRefPubMed

17.

Berwick DM, Murphy JM, Goldman PA, Ware JE Jr, Barsky AJ, Weinstein MC (1991) Performance of a five-item mental health screening test. Med Care 29:169–176CrossRefPubMed

18.

Rosner B, Cook N, Portman R, Daniels S, Falkner B (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167:653–666CrossRefPubMed

19.

Rosner B (2006) Fundamentals of biostatisitcs, 6th edn. Thomson Brooks/Cole, Belmont

20.

Papakostas GI, Miller KK, Petersen T, Sklarsky KG, Hilliker SE, Klibanski A et al (2006) Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry 67:952–957CrossRefPubMed

21.

Kim S, Park YM (2013) Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study. PLoS ONE 8:e82749CrossRefPubMedPubMedCentral

22.

Cowen PJ, Sargent PA (1997) Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 11:345–348CrossRefPubMed

23.

Gordon C, Whale R, Cowen PJ (1998) Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology 137:201–202CrossRefPubMed

24.

Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Maki-Ikola O et al (1997) Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 20:419–433CrossRefPubMed

25.

Spigset O, Mjorndal T (1997) The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. J Clin Psychopharmacol 17:292–297CrossRefPubMed

26.

Urban RJ, Veldhuis JD (1991) A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 164:147–152CrossRefPubMed

27.

Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332–340PubMedPubMedCentral

28.

Price LH, Charney DS, Delgado PL, Anderson GM, Heninger GR (1989) Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 46:625–631CrossRefPubMed

29.

Maguire GA (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4):56–62PubMed

30.

Wieck A, Haddad PM (2003) Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences selective literature review. Br J Psychiatry 182:199–204CrossRefPubMed

31.

Amsterdam JD, Garcia-Espana F, Goodman D, Hooper M, Hornig-Rohan M (1997) Breast enlargement during chronic antidepressant therapy. J Affect Disord 46:151–156CrossRefPubMed

32.

Petit A, Piednoir D, Germain ML, Trenque T (2003) Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database. Therapie 58:159–163CrossRefPubMed

33.

National Center for Health Statistics. Health, United States 2004. With Chartbook on Trends in the Health of Americans. Hyattsville, MD 2004

34.

Khan A, Schwartz KA, Kolts RL, Brown WA (2007) BMI, sex, and antidepressant response. J Affect Disord 99:101–106CrossRefPubMed

35.

Kloiber S, Ising M, Reppermund S, Horstmann S, Dose T, Majer M et al (2007) Overweight and obesity affect treatment response in major depression. Biol Psychiatry 62:321–326CrossRefPubMed

36.

Lin CH, Chen CC, Wong J, McIntyre RS (2014) Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. J Affect Disord 161:123–126CrossRefPubMed

37.

Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D et al (2009) Body weight as a predictor of antidepressant efficacy in the GENDEP project. J Affect Disord 118:147–154CrossRefPubMed

38.

Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE et al (2005) Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol 8:59–63CrossRefPubMed

39.

Tworoger SS, Sorensen B, Chubak J, Irwin M, Stanczyk FZ, Ulrich CM et al (2007) Effect of a 12-month randomized clinical trial of exercise on serum prolactin concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 16:895–899CrossRefPubMed

40.

Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A et al (2010) Incidence of cancer and antidepressant medication: record linkage study. Int J Cancer 126:285–296CrossRefPubMed

41.

Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE (2000) Psychotropic medication use and risk of hormone-related cancers: the New York University Women’s Health Study. J Public Health Med 22:155–160CrossRefPubMed

Titel: Antidepressant use and circulating prolactin levels
verfasst von: Katherine W. Reeves
Olivia I. Okereke
Jing Qian
Shelley S. Tworoger
Megan S. Rice
Susan E. Hankinson
Publikationsdatum: 10.05.2016
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 7/2016
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-016-0758-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Antidepressant use and circulating prolactin levels